DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Connor, Joseph P ^a   Felder, Mildred ^a   Kapur, Arvinder ^a   Onujiogu, Nonyem ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; CD44V ANTIGEN; CD44V3 ANTIGEN; DECOY RECEPTOR 3; HEPARIN; HEPARIN LYASE; MESSENGER RNA; PLATINUM; PROTEOHEPARAN SULFATE; SYNDECAN 2; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RECURRENCE; CANCER RESISTANCE; CELL ASSAY; CELL DEATH; CELL STRAIN CAOV 3; CELL STRAIN OVCAR 3; CELL STRAIN SKOV3; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EXPOSURE; DRUG MEGADOSE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; OVARY CARCINOMA; PERITONEAL CAVITY; PROTEIN EXPRESSION; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR BINDING; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; LIGANDS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PLATINUM; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B;

EID: 84860812998     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-176     Document Type: Article

References (45)

1. Yu KY, Kwon B, Ni J, Zhai Y, Ebner R, Kwon BS. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999, 274(20):13733-13736. 10.1074/jbc.274.20.13733, 10318773.
2. Pitti RM, Marsters SA, Lawrence DA, Roy M, Kischkel FC, Dowd P, Huang A, Donahue CJ, Sherwood SW, Baldwin DT, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998, 396(6712):699-703. 10.1038/25387, 9872321.
3. Wu Y, Han B, Sheng H, Lin M, Moore PA, Zhang J, Wu J. Clinical significance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients. Int J Cancer 2003, 105(5):724-732. 10.1002/ijc.11138, 12740925.
4. Shen HW, Gao SL, Wu YL, Peng SY. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis. World J Gastroenterol 2005, 11(38):5926-5930.
5. Macher-Goeppinger S, Aulmann S, Wagener N, Funke B, Tagscherer KE, Haferkamp A, Hohenfellner M, Kim S, Autschbach F, Schirmacher P, et al. Decoy receptor 3 is a prognostic factor in renal cell cancer. Neoplasia 2008, 10(10):1049-1056. 2546583, 18813347.
6. Li H, Zhang L, Lou H, Ding I, Kim S, Wang L, Huang J, Di Sant'Agnese PA, Lei JY. Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus. Am J Clin Pathol 2005, 124(2):282-287. 10.1309/XK594E4B5WU82QR6, 16040301.
7. Hwang SL, Lin CL, Cheng CY, Lin FA, Lieu AS, Howng SL, Lee KS. Serum concentration of soluble decoy receptor 3 in glioma patients before and after surgery. Kaohsiung J Med Sci 2004, 20(3):124-127. 10.1016/S1607-551X(09)70095-6, 15124896.
8. Connor JP, Felder M. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecol Oncol 2008, 111(2):330-335. 10.1016/j.ygyno.2008.07.012, 18723214.
9. DiSaia P. Creaseman, W: Clinical Gynecologic Oncology fifth edn 1997, Mosby, St Louis MO.
10. Lin WW, Hsieh SL. Decoy receptor 3: a pleiotropic immunomodulator and biomarker for inflammatory diseases, autoimmune diseases and cancer. Biochem Pharmacol 2011, 81(7):838-847. 10.1016/j.bcp.2011.01.011, 21295012.
11. Cheng CP, Sytwu HK, Chang DM. Decoy receptor 3 attenuates collagen-induced arthritis by modulating T cell activation and B cell expansion. J Rheumatol 2011, 38(12):2522-2535. 10.3899/jrheum.110245, 21885501.
12. Chang YC, Chen TC, Lee CT, Yang CY, Wang HW, Wang CC, Hsieh SL. Epigenetic control of MHC class II expression in tumor-associated macrophages by decoy receptor 3. Blood 2008, 111(10):5054-5063. 10.1182/blood-2007-12-130609, 18349319.
13. Chang YC, Chan YH, Jackson DG, Hsieh SL. The glycosaminoglycan-binding domain of decoy receptor 3 is essential for induction of monocyte adhesion. J Immunol 2006, 176(1):173-180.
14. Shi G, Wu Y, Zhang J, Wu J. Death decoy receptor TR6/DcR3 inhibits T cell chemotaxis in vitro and in vivo. J Immunol 2003, 171(7):3407-3414.
15. Mueller AM, Pedre X, Killian S, David M, Steinbrecher A. The Decoy Receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fluid. J Neuroimmunol 2009, 209(1-2):57-64.
16. Hsu TL, Wu YY, Chang YC, Yang CY, Lai MZ, Su WB, Hsieh SL. Attenuation of Th1 response in decoy receptor 3 transgenic mice. J Immunol 2005, 175(8):5135-5145.
17. Hsu MJ, Lin WW, Tsao WC, Chang YC, Hsu TL, Chiu AW, Chio CC, Hsieh SL. Enhanced adhesion of monocytes via reverse signaling triggered by decoy receptor 3. Exp Cell Res 2004, 292(2):241-251. 10.1016/j.yexcr.2003.09.019, 14697332.
18. You RI, Chang YC, Chen PM, Wang WS, Hsu TL, Yang CY, Lee CT, Hsieh SL. Apoptosis of dendritic cells induced by decoy receptor 3 (DcR3). Blood 2008, 111(3):1480-1488.
19. Yang CR, Wang JH, Hsieh SL, Wang SM, Hsu TL, Lin WW. Decoy receptor 3 (DcR3) induces osteoclast formation from monocyte/macrophage lineage precursor cells. Cell Death Differ 2004, 11(Suppl 1):S97-107.
20. Yang CR, Hsieh SL, Ho FM, Lin WW. Decoy receptor 3 increases monocyte adhesion to endothelial cells via NF-kappa B-dependent up-regulation of intercellular adhesion molecule-1, VCAM-1, and IL-8 expression. J Immunol 2005, 174(3):1647-1656.
21. Tai SK, Chang HC, Lan KL, Lee CT, Yang CY, Chen NJ, Chou TY, Tarng DC, Hsieh SL. Decoy receptor 3 enhances tumor progression via induction of tumor-associated macrophages. J Immunol 2012, 188(5):2464-2471. 10.4049/jimmunol.1101101, 22287720.
22. Chang YC, Hsu TL, Lin HH, Chio CC, Chiu AW, Chen NJ, Lin CH, Hsieh SL. Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol 2004, 75(3):486-494.
23. Simon I, Liu Y, Krall KL, Urban N, Wolfert RL, Kim NW, McIntosh MW. Evaluation of the novel serum markers B7-H4, Spondin 2, and DcR3 for diagnosis and early detection of ovarian cancer. Gynecol Oncol 2007, 106(1):112-118. 10.1016/j.ygyno.2007.03.007, 17490732.
24. Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD. CD44v3 levels in primary cutaneous melanoma are predictive of prognosis: assessment by the use of tissue microarray. Int J Cancer 2006, 118(6):1460-1464. 10.1002/ijc.21504, 16187282.
25. Poncelet C, Walker F, Madelenat P, Bringuier AF, Scoazec JY, Feldmann G, Darai E. Expression of CD44 standard and isoforms V3 and V6 in uterine smooth muscle tumors: a possible diagnostic tool for the diagnosis of leiomyosarcoma. Hum Pathol 2001, 32(11):1190-1196. 10.1053/hupa.2001.28935, 11727257.
26. Suzuki H, Yamashiro K. Reduced expression of CD44 v3 and v6 is related to invasion in lung adenocarcinoma. Lung Cancer 2002, 38(2):137-141. 10.1016/S0169-5002(02)00176-9, 12399124.
27. Kuniyasu H, Oue N, Tsutsumi M, Tahara E, Yasui W. Heparan sulfate enhances invasion by human colon carcinoma cell lines through expression of CD44 variant exon 3. Clin Cancer Res 2001, 7(12):4067-4072.
28. Kuniyasu H, Chihara Y, Kubozoe T, Takahashi T. Co-expression of CD44v3 and heparanase is correlated with metastasis of human colon cancer. Int J Mol Med 2002, 10(3):333-337.
29. Montgomery E, Abraham SC, Fisher C, Deasel MR, Amr SS, Sheikh SS, House M, Lilliemoe K, Choti M, Brock M, et al. CD44 loss in gastric stromal tumors as a prognostic marker. Am J Surg Pathol 2004, 28(2):168-177. 10.1097/00000478-200402000-00003, 15043305.
30. Saegusa M, Machida D, Hashimura M, Okayasu I. CD44 expression in benign, premalignant, and malignant ovarian neoplasms: relation to tumour development and progression. J Pathol 1999, 189(3):326-337. 10.1002/(SICI)1096-9896(199911)189:3<326::AID-PATH425>3.0.CO;2-6, 10547593.
31. Essner JJ, Chen E, Ekker SC. Syndecan-2. Int J Biochem Cell Biol 2006, 38(2):152-156. 10.1016/j.biocel.2005.08.012, 16198615.
32. Park H, Kim Y, Lim Y, Han I, Oh ES. Syndecan-2 mediates adhesion and proliferation of colon carcinoma cells. J Biol Chem 2002, 277(33):29730-29736. 10.1074/jbc.M202435200, 12055189.
33. Han I, Park H, Oh ES. New insights into syndecan-2 expression and tumourigenic activity in colon carcinoma cells. J Mol Histol 2004, 35(3):319-326.
34. Kokenyesi R. Ovarian carcinoma cells synthesize both chondroitin sulfate and heparan sulfate cell surface proteoglycans that mediate cell adhesion to interstitial matrix. J Cell Biochem 2001, 83(2):259-270. 10.1002/jcb.1230, 11573243.
35. Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, Slade RJ, Martin-Hirsch P, Gallagher JT, Jayson GC. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res 2004, 10(15):5178-5186. 10.1158/1078-0432.CCR-03-0103, 15297422.
36. Zhang W, Zong CS, Hermanto U, Lopez-Bergami P, Ronai Z, Wang LH. RACK1 recruits STAT3 specifically to insulin and insulin-like growth factor 1 receptors for activation, which is important for regulating anchorage-independent growth. Mol Cell Biol 2006, 26(2):413-424. 10.1128/MCB.26.2.413-424.2006, 1346890, 16382134.
37. Huang JW, Chuang NN. Shift syndecan-2 from RACK1 to caveolin-2 upon transformation with oncogenic ras. Biochem Biophys Res Commun 2006, 350(1):227-232. 10.1016/j.bbrc.2006.09.035, 16997272.
38. Huang JW, Chen CL, Chuang NN. Trap RACK1 with Ras to mobilize Src signaling at syndecan-2/p120-GAP upon transformation with oncogenic ras. Biochem Biophys Res Commun 2005, 330(4):1087-1094. 10.1016/j.bbrc.2005.02.189, 15823555.
39. Huang JW, Chen CL, Chuang NN. P120-GAP associated with syndecan-2 to function as an active switch signal for Src upon transformation with oncogenic ras. Biochem Biophys Res Commun 2005, 329(3):855-862. 10.1016/j.bbrc.2005.02.045, 15752734.
40. Chu LY, Chen YH, Chuang NN. Dimerize RACK1 upon transformation with oncogenic ras. Biochem Biophys Res Commun 2005, 330(2):474-482. 10.1016/j.bbrc.2005.03.011, 15796907.
41. Tan DS, Rothermundt C, Thomas K, Bancroft E, Eeles R, Shanley S, Ardern-Jones A, Norman A, Kaye SB, Gore ME. "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol 2008, 26(34):5530-5536. 10.1200/JCO.2008.16.1703, 18955455.
42. Melichar B, Fridrichova P, Tomsova M, Malirova E. Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy. Eur J Gynaecol Oncol 2009, 30(3):323-325.
43. Foulkes WD. BRCA1 and BRCA2: chemosensitivity, treatment outcomes and prognosis. Fam Cancer 2006, 5(2):135-142. 10.1007/s10689-005-2832-5, 16736282.
44. Husain A, He G, Venkatraman ES, Spriggs DR. BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). Cancer Res 1998, 58(6):1120-1123.
45. Horiuchi A, Wang C, Kikuchi N, Osada R, Nikaido T, Konishi I. BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells. Biomark Insights 2007, 1:49-59. 2716781, 19690636.